Article
Roche joins AbbVie in stepping on Vertex's turf, betting $96M on an alternative CF approach
Rating:
0.0
Views:
202
Likes:
1
Library:
1
James Sabry's latest deal spree is taking Roche back to a field where Genentech nabbed one of its first FDA approvals: cystic fibrosis. Turning to Enterprise Therapeutics out of Brighton, England, Roche is acquiring a portfolio of TMEM16A potentiators, which promises to treat all CF patients regardless of CFTR genotype
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value